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ttp://dx.doi.org/10.1016/j.ajpath.2014.10.008Failure to inhibit hepatic gluconeogenesis is a major mechanism contributing to fasting hyperglycemia in
type 2 diabetes and, along with steatosis, is the hallmark of hepatic insulin resistance. Obesity is associated
with chronic inﬂammation in multiple tissues, and hepatic inﬂammation is mechanistically linked to both
steatosis and hepatic insulin resistance. Here, we delineate a role for coagulation signaling via tissue factor
(TF) and proteinase-activated receptor 2 (PAR2) in obesity-mediated hepatic inﬂammation, steatosis, and
gluconeogenesis. In diet-induced obese mice, TF tail signaling independent of PAR2 drives CD11bþCD11cþ
hepatic macrophage recruitment, and TFePAR2 signaling contributes to the accumulation of hepatic CD8þ T
cells. Transcripts of key pathways of gluconeogenesis, lipogenesis, and inﬂammatory cytokines were
reduced in high-fat dietefed mice that lack the cytoplasmic domain of TF (F3) (TFDCT) or that are deﬁcient in
PAR2 (F2rl1), as well as by pharmacological inhibition of TFePAR2 signaling in diet-induced obese mice.
These gluconeogenic, lipogenic, and inﬂammatory pathway transcripts were similarly reduced in response
to genetic ablation or pharmacological inhibition of TFePAR2 signaling in hematopoietic cells and were
mechanistically associated with activation of AMP-activated protein kinase (AMPK). These ﬁndings indicate
that hematopoietic TFePAR2 signaling plays a pivotal role in the hepatic inﬂammatory responses, steatosis,
and hepatic insulin resistance that lead to systemic insulin resistance and type 2 diabetes in obesity.
(Am J Pathol 2015, 185: 524e535; http://dx.doi.org/10.1016/j.ajpath.2014.10.008)Supported by NIH grants R01 HL071146 (F.S.), R01 HL0104232 (F.S.),
and R01 HL077753 (W.R.) and by a grant from the Diabetes National
Research Group (F.S.).
Disclosures: None declared.The liver plays a central role in maintaining glucose
homeostasis and lipid metabolism, and alterations in liver
function underlie the development of cardiovascular and
metabolic disease.1e3 A large proportion of obese patients
develops hepatic steatosis, which leads to nonalcoholic fatty
liver disease (NAFLD), a disease that ranges from fatty liver
to the more severe condition of steatohepatitis, which can, if
left unchecked, progress to ﬁbrosis and cirrhosis in up to 25%
of patients.4,5 Alterations of hepatic synthesis of procoagulant
and prothrombotic pathway proteins observed in obese sub-
jects with NAFLD further exacerbate the cardiovascular and
metabolic risk in this population.6e9 Another feature of
obesity and NAFLD is hepatic inﬂammation, reﬂected in the
increased production of proinﬂammatory cytokines and
acute-phase proteins and by the activation of pathwaysstigative Pathology.
.regulated by inhibitor of nuclear factor kappa-B kinase sub-
unit beta (IKK-b) and Jun N-terminal kinase (JNK).10,11
Recent studies suggest a role for hepatic inﬂammation and
immune cells in the regulation of both NAFLD and hepatic
insulin resistance. A macrophage population distinct from
resident Kupffer cells is recruited to the liver during obesity,
and proinﬂammatory activation of liver macrophages is
linked to both insulin resistance and NAFLD.12,13 However,
mechanisms that contribute to the inﬂammatory state of the
obese liver and pathways that drive the recruitment of
TFePAR2 Signaling in the Obese Livermacrophages and other immune cells, including T cells,
remain poorly characterized.
Strong clinical evidence suggests that a TF-mediated
coagulation pathway is up-regulated in obesity and in
metabolic syndrome. Obese subjects have higher plasma
concentrations of coagulation factor VII (FVII), increased
levels of thrombin and thrombineantithrombin complexes,
and increased circulating monocyte TF procoagulant
activity.14e16 TF initiates the coagulation cascade by
serving as the cell surface receptor for FVIIa. In addition to
its coagulation functions, TF activates signaling cascades
with numerous roles in both normal physiology and dis-
ease.17e19 The TFeFVIIa complex initiates direct TF
signaling by activating proteinase-activated receptor 2
(PAR2) and regulates cell migration via a mechanism
involving phosphorylation of the TF cytoplasmic domain.20
Pharmacological and genetic approaches using an antibody
(10H10) that speciﬁcally blocks TFePAR2 signaling or
mice that lack the cytoplasmic domain of TF or PAR2-
deﬁcient mice have provided evidence for TFePAR2
signaling in cancer progression,19,21 angiogenesis,21,22 and
inﬂammation.23e25 Using such pharmacological and
genetic approaches we have established a role for
TFePAR2 signaling in the development of obesity and
insulin resistance.26 We have shown that nonhematopoietic
cell TFeVIIaePAR2 signaling promoted obesity via
regulation of overall metabolism and energy expenditure.
By contrast, TFePAR2 signaling in hematopoietic cells
attenuated adipose tissue macrophage recruitment and
inﬂammation and led to increased systemic insulin sensi-
tivity. Although these studies suggested that TF-mediated
adipose dysfunction may contribute to obesity and sys-
temic insulin resistance, the contribution of hepatic TF
signaling to systemic glucose homeostasis and hepatic
dysfunction (NAFLD and hepatic insulin resistance)
remained to be determined. In the present study, we used
genetic and pharmacological tools to unravel a role for TF
and PAR2 signaling in hepatic steatosis and insulin resis-
tance. Here, we show that hematopoietic TFePAR2
signaling blunts AMPK activation, increases hepatic
inﬂammation, and activates pathways of lipogenesis and
gluconeogenesis that contribute to hepatic steatosis and
insulin resistance, respectively. At the cellular level, TF and
PAR2 regulate hepatic recruitment and proinﬂammatory
activation of a population of CD11bþCD11cþ macrophages
and CD8þ T cells. Our ﬁndings suggest that limiting steatosis
and hepatic glucose production by inhibiting TFePAR2
signaling may provide a novel therapeutic approach for the
treatment of type 2 diabetes driven by obesity.
Materials and Methods
Mice
Mice lacking the TF cytoplasmic domain (TFDCT),
PAR2-deﬁcient mice (F2rl1/; hereafter Par2/), andThe American Journal of Pathology - ajp.amjpathol.orgTFDCT/Par2/ mice were all in the C57BL/6J back-
ground. Humanized TF knock-in mice (TFKI) in the
C57BL/6J background were from Dr. Mark Anderson
(Johnson & Johnson Pharmaceutical Research & Devel-
opment, Spring House, PA). Male mice were fed either a
high-fat diet (HFD) (60% kcal from fat) or a low-fat diet
(LFD) (10% kcal from fat) (Research Diets, New Bruns-
wick, NJ) beginning at 6 to 8 weeks of age. Bone marrow
(BM) chimeras were generated by injecting 5  106 to
10  106 BM cells at 4 to 6 hours after lethal irradiation
of mice. After engraftment under antibiotic prophylaxis for
6 weeks, mice were fed a HFD for 16 to 20 weeks. BM
donors typically carried a transgene for green ﬂuorescent
protein (GFP) [C57BL/6-Tg(CAG-EGFP)131Osb/LeySopJ;
Jackson Laboratory, Bar Harbor, ME], and reconstitution
efﬁciency was determined by analyzing GFP positivity in
isolated liver mononuclear cells.
All experiments were approved by the animal ethics
committee of the Torrey Pines Institute for Molecular
Studies and the Institutional Animal Care and Use Com-
mittee of the Scripps Research Institute.
Plasma Insulin, Glucose, and Insulin Tolerance Test
Fasting plasma insulin levels were measured using a mouse
ultrasensitive insulin enzyme-linked immunosorbent assay
kit (catalog number 80-INSMSU-E01; ALPCO Diagnostics,
Salem, NH) according to the manufacturer’s instructions.
Plasma glucose was measured with a glucometer (Bayer,
Leverkusen, Germany). To test for insulin tolerance, mice
were injected with insulin (0.75 U/kg; Eli Lilly, Indian-
apolis, IN), and glucose concentrations were measured in
blood samples from tail bleeds at baseline and at 15, 30, 60,
90, and 120 minutes after injection.
Western Blot Analysis
Total protein was extracted from snap-frozen livers in the
presence of protease and phosphatase inhibitors, and
equal amounts of proteins were separated by 10% SDS
PAGE and transferred to nitrocellulose membranes. The
membranes were probed with antibodies to AMPKa
and phosphorylated AMPKa (p-AMPKa T172) (Cell
Signaling Technology, Danvers, MA). Immunoreactive
proteins were visualized using an Amersham enhanced
chemiluminescence kit (GE Healthcare, Little Chalfont,
UK). For analysis of insulin-dependent Akt phosphory-
lation, mice were injected with 0.75 U/kg insulin via the
tail vein 10 minutes before harvesting liver samples for
Western blotting using antibodies to Akt and p-Akt (Cell
Signaling Technology).
Quantiﬁcation of Tissue and Plasma Triglyceride
Liver samples (20 to 30 mg) were homogenized for 10
minutes in 1 mL isopropanol using a Bio-Gen Pro200525
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Figure 1 Hematopoietic TFePAR2 signaling contributes to gluconeogenesis and insulin resistance during diet-induced obesity. A and B: TF (A) and PAR2 (B)
mRNA in the liver of male C57BL/6J WT mice fed a LFD (10% fat) or a HFD (60% fat) for 16 weeks. C and D: Hepatic G6Pase (C) and PEPCK-1 (D) mRNA in LFD-fed
WT mice and HFD-fed WT, TFDCT, Par2/, and double-deﬁcient TFDCT/Par2/ mice. E: Western blot analysis of insulin-induced p-Akt levels in liver from HFD-fed
WT, TFDCT, or Par2/ mice. F: HFD-fed TFKI mice (16 weeks) were treated intraperitoneally with either 20 mg/kg anti-human TF signalingeselective monoclonal
antibody 10H10 or IgG control twice a week for 3 weeks while continuing on the HFD, after which fasting plasma glucose and insulin were measured and the mice
were subjected to an insulin tolerance test. For this test, mice were injected with 0.75 U/kg insulin, and blood glucose was determined at intervals from 0 to 120
minutes. Relative expression of liver G6Pase and PEPCK-1 mRNA was also tested. G: G6Pase and PEPCK-1 mRNA in liver from HFD-fed (16 weeks) WT, TFDCT, or
Par2/ BM chimeras in C57BL/6J WT mice. H: Hepatic G6Pase and PEPCK-1 mRNA expression from DIO TFKI BM chimeras at 24 hours after receiving 20 mg/kg
anti-human TF 10H10, compared with obese TFKI BM chimeras receiving nonspeciﬁc IgG. Data are expressed as means  SD. n Z 8 to 12 (AeD); n Z 5 (E);
nZ 8 (F); nZ 8 to 10 (G); nZ 6 to 8 (H). *P < 0.05, **P < 0.01, and ***P < 0.001. BM, bone marrow; DIO, diet-induced obesity; DKO, double-deﬁcient
(TFDCT/Par2/); G6P, G6Pase; HFD, high-fat diet; LFD, low-fat diet; PAR2, proteinase-activated receptor 2; TF, tissue factor; TFDCT, lacking the cytoplasmic
domain of TF; TFKI, TF knock-in; WT, wild type.
Wang et alhomogenizer (Pro Scientiﬁc, Oxford, CT) and centrifuged at
2000 g for 10 minutes. From the recovered supernatant, 100
mL was dried in a SpeedVac vacuum system (Thermo Fisher
Scientiﬁc, Waltham, MA); the resulting pellet was dissolved in
isopropanol and used for determination of triglyceride content
with a triglyceride E test (Wako Chemicals USA, Richmond,
VA). Plasma triglyceride was measured directly using the
Wako triglyceride E test according to the manufacturer’s
instructions.
Isolation of Liver MNCs, Flow Cytometry, and Cell
Selection
Mouse livers were harvested and ﬁnely diced with a new
scalpel in phosphate-buffered saline and homogenized in a
six-well plate using a plunger; the resulting cell suspension
was passed through a 100-mm nylon cell strainer (BD Falcon;
BD Biosciences, San Jose, CA). Cells were washed with
phosphate-buffered saline and pelleted via centrifugation at526400  g for 10 minutes at 4C. The supernatant was
discarded, and cells were suspended in 36% Percoll
(GE Healthcare). This suspension was thoroughly mixed and
centrifuged at 500  g for 10 minutes at room temperature
with the brake off. The supernatant was removed gently, and
the resulting pellet was washed with red blood cell lysis
buffer before repelleting and collection of liver mononuclear
cells (MNCs).
For ﬂow cytometry, MNCs were blocked with anti-
FcrR (eBioscience, San Diego, CA) and stained with
ﬂuorescence-labeled monoclonal antibodies (eBioscience)
in the dark at 4C for 30 minutes. Cells were analyzed on
a BD LSR II ﬂow cytometer (BD Biosciences) using
FlowJo software version 10 (Tree Star, Ashland, OR). For
cell fractionation, liver MNCs were incubated with CD8
or CD11b microbeads (Miltenyi Biotec, Auburn, CA),
and corresponding CD8þ or CD11bþ cells were enriched
by positive magnetic-activated cell sorting according to
the manufacturer’s protocol (Miltenyi Biotec).ajp.amjpathol.org - The American Journal of Pathology
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Figure 2 Hematopoietic TFePAR2 signaling increases pathways that drive steatosis during diet induced obesity. A and B: Hepatic SREBP-1c and
FAS mRNA in LFD-fed WT and HFD-fed WT, TFDCT, Par2/, and TFDCT/Par2/ double-deﬁcient mice. C: HFD-fed TFKI mice (16 weeks) were treated
intraperitoneally with either 20 mg/kg anti-human TF signalingeselective monoclonal antibody 10H10 or IgG control twice a week for 3 weeks while
continuing on HFD; hepatic SREBP-1c and FAS mRNA levels were then determined. D: Hematoxylin and eosinestained section of liver, with liver and
plasma triglyceride levels from HFD-fed TFKI mice treated with either IgG or 10H10 (as in C). E: SREBP-1c and FAS mRNA in liver from 16 weeks HFD-
fed WT, TFDCT, or Par2/ BM chimeras in C57BL/6J WT mice. F: Hepatic SREBP-1c and FAS mRNA expression from DIO TFKI BM chimeras at 24 hours
after receiving 20 mg/kg anti-human TF 10H10, compared with obese TFKI BM chimeras receiving nonspeciﬁc IgG. Data are expressed as means 
SD. n Z 8 to 12 (A and B); n Z 8 (C and D); n Z 8 to 10 (E); n Z 6 to 8 (F). *P < 0.05, **P < 0.01, and ***P < 0.001. DKO, double-deﬁcient
(TFDCT/Par2/).
TFePAR2 Signaling in the Obese LiverRT-qPCR
cDNAs synthesized from total RNA (TRIzol reagent; Life
Technologies, Carlsbad, CA) were analyzed by real-time
quantitative PCR with reverse transcription (RT-qPCR) with
gene-speciﬁc primer sets (Life Technologies) and SYBR
Green PCR master mix (PerkinElmer, Waltham, MA) in an
iCycler thermal cycler (Bio-Rad Laboratories, Hercules,
CA).26 Relative gene expression levels were calculated after
normalization to 18S rRNA using the DDCT method (Bio-
Rad Laboratories). The 18S expression was stable in the
samples measured. Separate control experiments demon-
strated that the efﬁciencies of target and reference (ie, 18S)
ampliﬁcations were equal, thus validating the use of DDCT
for all of the transcripts measured.
Statistical Analysis
Statistical signiﬁcance of differences between two groups
was analyzed using the unpaired Student’s t-test.The American Journal of Pathology - ajp.amjpathol.orgResults
Hematopoietic TFePAR2 Signaling Contributes to
Pathways that Drive Gluconeogenesis and Steatosis
during Diet-Induced Obesity
Although under normal conditions insulin suppresses
hepatic glucose production (gluconeogenesis), the ability of
insulin to shut down hepatic glucose production is dimin-
ished during a state of hepatic insulin resistance, resulting in
hyperglycemia and type 2 diabetes. To determine the
contribution of TF and PAR2 signaling to hepatic insulin
resistance during obesity, we initially determined whether
these proteins are induced in the liver during weight gain.
Compared with wild-type (WT) mice fed a LFD for 16
weeks, WT mice fed a HFD had higher levels of TF and
PAR2 mRNA in the liver (Figure 1, A and B). A major
mechanism by which insulin inhibits hepatic glucose output
is regulation of the expression of rate-limiting gluconeo-
genic genes, such as PCK1 [encoding phosphoenolpyruvate527
CD
11
b
CD11c
LFD HFD
GatedonF4/80+ cellsA
C
D
4+
( %
)
L FD H FD
0
10
20
30
40
50 **
**
**
D
10
   
   
 1
0 
   
   
10
   
   
 1
0 
   
   
10
10
   
   
 1
0 
   
   
10
   
   
 1
0 
   
   
10
10       10       10       10       10 10       10       10       10       10
CD4
GatedonCD3+ cellsC
CD
8 10
   
   
 1
0 
   
   
10
   
   
 1
0 
   
   
10
10
   
   
 1
0 
   
   
10
   
   
 1
0 
   
   
10
10       10       10       10       10 10       10       10       10       10
GatedonCD3+ cells
C
D
11
b+
C
D
11
c+
(%
)
L FD H F D
0
20
40
60 *
B
C
D
1 1
b +
C
D
1 1
c-
(%
)
LFD H FD
0
20
40
60 **
GatedonF4/80+ cells
C
D
8+
(%
)
(g
at
ed
on
CD
3+
)
LFD H FD
0
5
10
15
20 *
*
TF
+
(%
)
CD
11
b+
C D
11
c-
CD
11
b+
C D
11
c+
0
20
40
60
80
F
PA
R 2
m
RN
A
CD
8+
C D
11
b+
0
1
2
3
4
5
(r
el
at
iv
e)
G
TF
m
R
N
A
(r
el
a t
iv
e )
CD
8+
CD
11
b+
0
5
10
15
20E
Gated on F4/80
CD
11
b
CD11c GFPGFP
100
80
60
40
20
0
C
o
u
n
t
H
10 10 10
FITC - A
50
40
30
20
10
0
10 10 10
FITC - A
C
o
u
n
t
Figure 3 Hepatic immune cell recruitment in
obesity. A and B: FACS and quantiﬁcation of liver
CD11bþCD11cþ and CD11bþCD11c macrophages
from male C57BL/6J WT mice fed a LFD or a HFD
for 16 weeks. C and D: FACS analysis and quanti-
ﬁcation of CD8þ and CD4þ T cells from liver of LFD-
fed and HFD-fed WT mice. E: TF mRNA expression
in CD8þ selected and CD11bþ selected cells from
liver of HFD-fed (16 weeks) DIO C57BL/6J WT
mice. F: Quantiﬁcation of TF expression in
CD11bþCD11cþ versus CD11bþCD11c macro-
phage populations in liver of HFD-fed DIO WT
mice. G: PAR2 mRNA expression in CD8þ versus
CD11bþ selected cells from liver of HFD-fed DIO
WT mice. H: FACS analysis of GFP-labeled
CD11bþCD11cþ and CD11bþCD11c macrophage
populations from liver of HFD-fed WT receiving BM
from GFP mice. Data are expressed as means  SD.
n Z 4 (AeH). *P < 0.05; **P < 0.01. FACS,
ﬂuorescence-activated cell sorting.
Wang et alcarboxykinase 1 (PEPCK-1)] and G6PC [encoding glucose-
6-phosphatase (G6Pase)]. Compared with WT LFD-fed
mice, transcripts of hepatic G6Pase and PEPCK-1 were
higher in HFD-fed WT mice (Figure 1, C and D). Impor-
tantly, compared with WT HFD-fed WT mice, mice deﬁ-
cient in the cytoplasmic domain of TF (TFDCT), PAR2, or
both had lower levels of both G6Pase and PEPCK-1
(Figure 1, C and D). The contribution of TF and PAR2 to
hepatic insulin resistance was further analyzed by measuring
insulin-mediated phosphorylation of Akt in the liver of
HFD-fed TFDCT or Par2/ mice. Compared with HFD-fed
WT mice, both TFDCT and Par2/ mice had signiﬁcantly
higher expression levels of liver p-Akt in response to acute
insulin injection (Figure 1E).
To directly link TFePAR2 signaling to regulation of
gluconeogenesis in the liver, we used a monoclonal anti-
body (10H10) to human TF that speciﬁcally blocks528TFeVIIaePAR2 signaling but not the downstream
TF-mediated coagulation. TF knock-in (TFKI) mice car-
rying human TF under the control of the endogenous
mouse TF promoter were fed a HFD for 8 weeks. Weight
gains in these mice were similar to those of WT mice (data
not shown). Groups of DIO TFKI mice were then treated
with 10H10 (20 mg/kg) or vehicle twice weekly for 3
weeks while continuing on the HFD. Compared with
vehicle-treated TFKI control mice, the 10H10-treated
TFKI mice exhibited improvements in systemic insulin
sensitivity, as indicated by reduced levels of fasting plasma
insulin, glucose, and improved sensitivity in the insulin
tolerance test (Figure 1F). Similarly, in our previous
studies we had shown that insulin sensitivity was improved
in HFD-fed TFDCT or Par2/ mice, as well as in HFD-fed
BM chimeras deﬁcient in either TF cytoplasmic domain or
PAR2 in hematopoietic cells.26 The improvements ofajp.amjpathol.org - The American Journal of Pathology
CPar2
Par2
Figure 4 TF and PAR2 contribute to hepatic immune cell recruitment in obesity. AeD: FACS analysis and quantiﬁcation of liver CD11bþCD11cþ and
CD11bþCD11c macrophage populations (A and B) and CD8þ and CD4þ T-cell populations (C and D) from male WT, TFDCT, or Par2/ mice fed a HFD for 16
weeks. E and F: FACS analysis and quantiﬁcation of liver macrophages (E) and T cells (F) from DIO TFKI mice treated with 20 mg/kg anti-human TF antibody
10H10 or IgG control twice a week for 3 weeks. Data are expressed as means  SD. n Z 4 (AeD); n Z 8 (E and F). *P < 0.05, **P < 0.01, and
***P < 0.001.
TFePAR2 Signaling in the Obese Liversystemic insulin sensitivity observed in long-term (3 weeks)
10H10-treated TFKI mice were also associated with reduced
levels of hepatic transcription of G6Pase and PEPCK-1
(Figure 1F). Thus, TFeVIIaePAR2 signaling drives path-
ways that contribute to increased glucose output and hepatic
insulin resistance during DIO.
BM chimeras were used to determine whether hemato-
poietic TFePAR2 signaling contributes to gluconeogenesis
during obesity. HFD-fed mice deﬁcient in the TF cytoplasmic
domain or PAR2 in hematopoietic cells also showed reduc-
tion in hepatic G6Pase and PEPCK-1 (Figure 1G). The
contribution of hematopoietic TFePAR2 signaling to
gluconeogenesis was further analyzed using TFKI mice to
generate BM chimeras in which hematopoietic cells were
humanized for TF. In these chimeric mice, human TF is
expressed only in hematopoietic cells, thus allowing us to
inhibit TFeVIIePAR2 signaling speciﬁcally in this cellular
compartment with the anti-human TF 10H10. Acute treat-
ment of DIO TFKI BM chimeras with a single dose of
antibody signiﬁcantly reduced hepatic G6Pase and PEPCK-1
(Figure 1H). Taken together, these results indicate that
hematopoietic TFePAR2 signaling contributes to hepaticThe American Journal of Pathology - ajp.amjpathol.orginsulin resistance by inducing key gluconeogenic pathways.
They additionally suggest the involvement of the liver in the
improvements in systemic glucose homeostasis previously
observed in hematopoietic TFePAR2 signaling-inhibited
DIO mice.26
In a previous study, we found that hepatic steatosis was
signiﬁcantly reduced in HFD-fed TFDCT or Par2/ mice,
and this phenotype was recapitulated in HFD-fed BM
chimeras deﬁcient in either TF cytoplasmic domain or
PAR2 in hematopoietic cells.26 However, we had not
determined the mechanisms by which TF and PAR2
signaling contributes to steatosis. In the present study, gene
expression of the lipogenic transcription factor sterol regu-
latory element-binding protein 1c (SREBP1c) and its target
enzyme, fatty acid synthase (FAS), was increased in HFD-
fed WT mice but was signiﬁcantly reduced in HFD-fed
TFDCT, Par2/, and double-deﬁcient TFDCT/Par2/
mice (Figure 2, A and B). Reductions were also observed
for these lipogenic mediators in the livers of DIO TFKI
mice in response to long-term treatment with 10H10
(Figure 2C), which provided direct evidence for TFePAR2
signaling in this response. Direct examination of steatosis529
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Figure 5 TFePAR2 signaling contributes to
hepatic inﬂammation. AeC: mRNA expression of
TNF-a, IFN-g, and IL-10 in liver of male WT
C57BL/6J mice fed a LFD or a HFD for 16
weeks (AeC) or in liver of DIO TFKI mice treated
with 20 mg/kg anti-human TF antibody 10H10 or
IgG control twice a week for 3 weeks (DeF).
Data are expressed as means  SD. n Z 8 to 12
(AeC); nZ 8 (DeF). *P < 0.05, ***P < 0.001.
Wang et alby histological examination and biochemical analysis
revealed signiﬁcantly reduced levels of triglyceride accu-
mulation and/or steatosis in 10H10-treated DIO TFKI mice;
however, plasma triglyceride levels remained unchanged in
10H10-treated mice (Figure 2D). These ﬁndings suggest
that one of the mechanisms by which TFePAR2 signaling
contributes to steatosis is up-regulation of de novo lipo-
genesis and also that TFePAR2 does not appear to
contribute hepatic triglyceride secretion.
The phenotype with reduced SREBP1c and FAS was
recapitulated in TF and PAR2 hematopoietic signaling-
deﬁcient HFD-fed BM chimeric mice and in HFD-fed
TFKI BM chimeras acutely treated with the antibody
10H10 (Figure 2, E and F). Thus, hematopoietic TFePAR2
signaling drives lipogenic pathways that contribute to hepatic
steatosis in obesity.
TF and PAR2 Contribute to Hepatic Immune Cell
Recruitment in Obesity
Although a number of studies suggest that hepatic inﬂamma-
tion contributes to hepatic insulin resistance and NAFLD,10e13
mechanisms and cell-speciﬁc contributions of hepatic inﬂam-
mation to the pathogenesis of these liver disorders are unclear.
Recent reports have also described a myeloid population that
is recruited to the liver from circulating monocytes during the
development of obesity.13 Nonetheless, the distinct functions
of recruited monocyte-derived hepatic macrophages and other
immune cells to obesity-associated hepatic dysfunction
are unclear.
To determine whether TF and PAR2 signaling contributes
to hepatic immune cell recruitment, we initially character-
ized the changes in the repertoire of macrophages and T530cells in the liver of WT mice in response to a HFD. FACS
analysis revealed an increase in the percentage of macro-
phages positive for the surface markers CD11b and CD11c
and a decrease in the percentage of CD11bþCD11c cells in
the liver of HFD-fed WT mice, compared with mice fed a
LFD (Figure 3, A and B). The percentage of CD8þ T cells
was further increased, but that of CD4þ T cells was lower,
in the liver of DIO HFD WT mice (Figure 3, C and D),
relative to lean LFD WT mice. We next determined the
relative expression of TF and PAR2 in the CD11bþ and
CD8þ cell populations in livers from DIO WT mice. FACS
analysis indicated that the CD11bþ cell populations was
predominantly (70%) composed of macrophages, and that
CD8þ cells were predominantly (90%) T cells (Supplemental
Figure S1). CD11bþ and CD8þ cell populations were iso-
lated using paramagnetic microbeads coated with antibodies
to CD11b and CD8, respectively. Fractionation efﬁciency
indicated efﬁcient puriﬁcation of these cell populations
(Supplemental Figure S2), with minimal crossover. TF
expression was higher in the hepatic CD11bþ population
(predominantly macrophages), relative to the CD8þ popula-
tion (mostly T cells) (Figure 3E). FACS analysis indicated
that, in macrophages, TF was higher in the CD11bþCD11cþ
subpopulation relative to CD11bþCD11c cells (Figure 3F).
By contrast, PAR2 gene expression was relatively higher
in the CD8þ T cells than in the CD11bþ macrophages
(Figure 3G).
To determine whether these macrophage populations were
recruited from hematopoietic cells from BM, we generated
BM chimeric mice in which BM was transplanted from WT
GFP donor mice to WT non-GFP recipients. The chimeric
mice were fed a HFD for 16 weeks and then immune cell
populations recruited to the liver were determined byajp.amjpathol.org - The American Journal of Pathology
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Figure 6 Hematopoietic TFePAR2 signaling
contributes to hepatic inﬂammation in obesity.
mRNA expression of TNF-a, IFN-g, and IL-10
from HFD-fed (16 weeks) WT, TFDCT, or Par2/
BM chimeras in C57BL/6J WT mice (AeC) or in
liver of DIO TFKI BM chimeras 24 hours after
receiving 20 mg/kg anti-human TF 10H10,
compared with obese TFKI BM chimeras receiving
nonspeciﬁc IgG (DeF). Data are expressed as
means  SD. n Z 8 to 10 (AeC); n Z 6 to 8
(DeF). *P < 0.05, ***P < 0.001.
TFePAR2 Signaling in the Obese LiverFACS analysis. Both the CD11bþCD11cþ and the
CD11bþCD11c populations in the liver were predomi-
nantly GFPþ (Figure 3H), which indicates that these
macrophage populations represent hematopoietic pop-
ulations recruited to the liver during DIO and are distinct
from resident Kupffer cells, which are long-lived and
radiation-resistant self-renewing embryo-derived local
macrophages.27
Compared with HFD-fed WT mice, the percentage of
CD11bþCD11cþ macrophages was decreased in HFD-fed
TFDCT mice, but not in HFD-fed Par2/ mice (Figure 4,
A and B). No changes were observed in the relative levels
of CD11bþCD11c cells in HFD-fed TFDCT or Par2/CD
8+
CD
11
b+
0
5
10
15
20
*
TN
F-
α
 m
R
N
A
(r
el
at
iv
e)
C D
8+
C D
11
b +
0
2
4
6
8
10 ***
***
**
**
**
IF
N-
γ  
m
RN
A
(r
el
at
iv
e)
CD
8+
0
1
2
3
4
5
IL
-1
0 
m
R
N
A
(r
el
at
iv
e)
A B C
TN
F-
α
 m
R
N
A
(r
el
at
iv
e)
WT
0
1
2
3
4
 C D 8+
TF
ΔC
T
IF
N-
γ  
m
RN
A
(r
el
at
iv
e)
WT
0
1
2
3
4
5
 C D 8+
IL
-1
0 
m
R
N
A
(r
el
at
iv
e)
WT
0
5
10
15D E F
TF
ΔC
T
The American Journal of Pathology - ajp.amjpathol.orgmice (Figure 4, A and B), compared with WT, but CD8þ T
cells decreased and CD4þ T cells increased (Figure 4, C
and D). To directly determine the immune cells that are
recruited to the obese liver via TFePAR2 signaling, we
treated DIO TFKI mice for 3 weeks with 10H10 to block
TFePAR2 signaling. The various immune populations
were determined using FACS analysis. In these TFKI
mice, a speciﬁc reduction was observed only for the
CD8þ T-cell population (Figure 4, E and F). Taken
together, these results suggest that TF tail signaling
independent of PAR2 drives CD11bþCD11cþ hepatic
macrophage recruitment and that TFePAR2 signaling
contributes to CD8þ T cell recruitment.**
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Figure 7 TFePAR2 signaling increases in-
ﬂammatory responses in hepatic immune cells.
AeC: mRNA expression of TNF-a, IFN-g, and IL-10
in CD8þ selected and CD11bþ selected cells from
liver of HFD-fed WT C57BL/6J mice. DeF: mRNA
expression of TNF-a and IFN-g in CD8þ selected
cells (D and E) and mRNA expression of IL-10 in
CD11bþ selected cells (F) from liver of HFD-fed
WT, TFDCT, or Par2/ mice. Data are expressed
as means  SD. n Z 3. *P < 0.05, **P < 0.01,
***P < 0.001.
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Figure 8 TFePAR2 signaling blunts hepatic AMPK activation. Repre-
sentative Western blot analysis and quantiﬁcation of liver p-AMPK (Thr
172) and AMPK from long-term (3 weeks) 10H10-treated DIO TFKI mice (A)
and DIO TFKI BM chimeras treated acutely (24 hours) with 10H10 (B),
compared with control IgG. Data are expressed as means  SD. n Z 4.
*P < 0.05 for control IgG versus antibody 10H10-treated.
Wang et alTF and PAR2 Contribute to Proinﬂammatory Responses
of Hepatic Immune Cells
To establish the contribution of TF and PAR2 signaling in
hepatic inﬂammation, we initially determined the tran-
scription of key inﬂammatory genes in liver from mice fed
either a LFD or a HFD for 16 weeks. Expression of TNF-a,
IFN-g, and IL-10 was increased in total liver RNA extracts
from WT HFD-fed mice, compared with their lean LFD-fed
counterparts (Figure 5, AeC). To conﬁrm the contribution
of TFePAR2 signaling to this inﬂammatory proﬁle, we
treated DIO TFKI mice long term with 10H10. In these
mice, TNF-a and IFN-g gene expression was reduced, and
IL-10 expression was increased (Figure 5, DeF), indicating
that TFePAR2 signaling contributes to the hepatic proin-
ﬂammatory changes that accompany obesity.
Because our BM transplantation studies indicated that TF
and PAR2 signaling in hematopoietic cells drives pathways
of hepatic insulin resistance and steatosis (Figures 1 and 2),
we analyzed whether these changes in inﬂammatory gene
expression are mediated by hematopoietic TFePAR2
signaling. HFD-fed BM chimeras deﬁcient in the TF cyto-
plasmic domain or PAR2 in hematopoietic cells exhibited
signiﬁcantly lower levels of hepatic TNF-a and IFN-g
mRNA, but increased expression of IL-10 (Figure 6, AeC).
HFD-fed TFKI BM chimeric mice with human TF in the
hematopoietic compartment were treated acutely with
10H10 to speciﬁcally inhibit TFePAR2 signaling in this
compartment. Measures of hepatic inﬂammatory gene
expression in these mice also indicated decreased levels of
TNF-a and IFN-g mRNA, but IL-10 levels were induced
(Figure 6, DeF). Taken together, these results suggest that
TFePAR2 signaling in hematopoietic cells contributes to
hepatic inﬂammation during DIO obesity.
To determine the contribution of TF and PAR2 signaling
in macrophages and CD8þ T cells in the inﬂammatory
response during DIO, we measured hepatic inﬂammatory
gene expression in these immune cells in DIO WT mice.
Notably, expression of TNF-a and IFN-g was higher in
CD8þ cells (relative to the CD11bþ macrophage popula-
tion) in the livers of DIO WT mice (Figure 7, A and B), but
expression of these cytokines in CD8þ cells was signiﬁ-
cantly lower in TFDCT and Par2/ mice (Figure 7, D and
E). By contrast, IL-10 gene expression was relatively higher
in CD11bþ cells, compared with CD8þ cells (Figure 7C).
IL-10 expression in CD11bþ cells was further increased in
TFDCT and Par2/ mice (Figure 7F).
TFePAR2 Signaling Blunts Hepatic AMPK Activation
AMPK plays crucial roles in the regulation of hepatic
glucose and lipid metabolism and is a major target for the
treatment of metabolic disease.28e30 Enhancing hepatic
AMPK activity reduces hepatic insulin resistance and
steatosis via ameliorating pathways of gluconeogenesis
and inhibiting lipogenesis, respectively.31e36 However,532regulatory mechanisms of AMPK in the liver are not well
understood. Because PAR2 signaling is known to blunt
AMPK activity via the b-arrestin pathway,37 we hypothe-
sized that, in obesity, TFePAR2 signaling in the liver may
blunt AMPK activity and thereby lead to the downstream
effects of hepatic insulin resistance and steatosis. To test
this hypothesis, we measured AMPK activity (phosphor-
ylation at threonine 172) in liver of TFKI mice that were
treated for 3 weeks with 10H10 to inhibit TFePAR2
signaling. Western blot analysis indicated that hepatic
AMPK activity was signiﬁcantly increased in 10H10-
treated TFKI mice, compared with TFKI mice treated
with IgG (Figure 8A). To determine whether hematopoietic
TFePAR2 signaling similarly blunts AMPK activity,
we treated DIO TFKI BM chimeras acutely with 10H10
and analyzed hepatic AMPK activity. p-AMPK wasajp.amjpathol.org - The American Journal of Pathology
TFePAR2 Signaling in the Obese Liversigniﬁcantly increased in the liver of DIO TFKI BM
chimeric mice treated with 10H10, compared with control
IgG-treated mice (Figure 8B).Discussion
Obesity, a major risk factor for type 2 diabetes, is often
linked with abnormal regulation of hepatic glucose pro-
duction and steatosis. The liver is crucial for maintaining
glucose homeostasis and is the major site of endogenous
glucose production. Inadequate insulin-mediated suppres-
sion of hepatic gluconeogenesis is a manifestation of hepatic
insulin resistance and is pivotal in the pathogenesis of type 2
diabetes. We had demonstrated that mice lacking TF cyto-
plasmic domain or PAR2 in the whole body or only in the
hematopoietic compartment showed improved glucose
tolerance, insulin sensitivity, and decreased hepatic stea-
tosis.26 Although these improvements were associated with
reductions in adipose inﬂammation, the contribution of TF
signaling in the liver to improvements in whole-body
glucose homeostasis and steatosis remained unclear. With
the present study, we have demonstrated that hepatic
TFePAR2 signaling promotes pathways of lipogenesis and
gluconeogenesis that contribute to steatosis and hepatic
insulin resistance, respectively.
Transcripts of lipogenic (SREBP1c, FAS) and gluco-
neogenic (PEPCK-1, G6Pase) proteins were lower in the
livers of HFD-fed mice lacking the TF cytoplasmic domain
or PAR2 in hematopoietic cells and in response to inhibition
of hematopoietic TFePAR2 signaling in DIO mice, indi-
cating a crucial role for TFePAR2 signaling in the hepatic
metabolic abnormalities associated with obesity. Previous
studies have shown that coagulation signaling mediated by
downstream thrombinePAR1 contributed to TNF-a and
MCP-1 expression, but not steatosis, in mice fed a diet
deﬁcient in methionine and choline.38 In mice fed a Western
diet, PAR1 and hematopoietic-derived TF contributed to
hepatic inﬂammation and steatosis.8
Similar to adipose inﬂammation, hepatic inﬂammation
involving inﬂammatory responses in local immune cells is
linked to pathways that drive hepatic insulin resistance and
NAFLD in response to obesity.12,13 However, neither the
inﬂammatory response in the obese liver with respect to
macrophages and other immune cells nor the signals that
activate their proinﬂammatory responses are well charac-
terized. In addition to Kupffer cells (resident macrophages
in liver), obesity promotes the recruitment of a morpho-
logically and functionally distinct monocyte-derived
macrophage cell population.13 Depletion of both Kupffer
cells and recruited hepatic macrophages using gadolinium
or clodronate shows that liver macrophages are a causal
factor in obesity-induced hepatic insulin resistance.39
Deletion of PPARd within hematopoietic cells polarizes
the liver resident macrophages (Kupffer cells) toward an M1
classically activated state and reduces systemic insulinThe American Journal of Pathology - ajp.amjpathol.orgsensitivity.12 In these studies, however, the speciﬁc contri-
butions of Kupffer cells versus recruited macrophages to the
observed phenotype is unclear. Gadolinium and clodronate
deplete all macrophages, but hematopoietic deletion of
PPARd is expected to delete PPARd only in the population
of recruited macrophages, and not in resident Kupffer cells,
which are long-lived and radiation-resistant self-renewing
embryo-derived cells.27
In the present study, a population of macrophages posi-
tive for the surface markers CD11b and CD11c was
signiﬁcantly increased in the liver in response to a HFD.
BM transplantation studies with GFP-labeled donors sug-
gest that positivity for CD11b and CD11c deﬁnes the pop-
ulation that is recruited to the liver in response to a HFD, a
population distinct from resident Kupffer cells. Mice deﬁ-
cient in the TF cytoplasmic domain (TFDCT) had decreased
levels of CD11bþCD11cþ macrophages, but no changes in
this macrophage population was observed in Par2/mice.
Thus, TF cytoplasmic tail signaling contributes to hepatic
macrophage recruitment independent of PAR2. The mech-
anism of TF-mediated macrophage recruitment to the obese
liver is consistent with other systems in which TF mediates
integrin-dependent signaling and cell migration independent
of PAR2.18,20,40,41 FACS analysis indicated that a HFD also
led to a signiﬁcant increase in hepatic CD8þ T cells, which
may also drive local inﬂammation. In this instance, both
TFDCT mice and Par2/ mice exhibited decreased levels of
hepatic CD8þ T cells in response to obesity. Inhibition of
TFePAR2 signaling in DIO TFKI mice similarly reduced
CD8þ T cells, which suggests a direct role for TFePAR2
signaling in the recruitment of hepatic CD8þ T cells. In DIO
WT mice, levels of proinﬂammatory cytokines TNF-a and
IFN-g were higher in hepatic CD8þ cells (predominantly
CD8þ T cells), relative to CD11bþ cells (primarily macro-
phages). CD8þ cell expression of these cytokines was
reduced in TFDCT and Par2/ mice. By contrast, levels of
the anti-inﬂammatory cytokine IL-10 were higher in hepatic
CD11bþ cells, relative to CD8þ cells, in DIO WT mice.
IL-10 levels in CD11bþ cells were further increased in
HFD-fed TFDCT mice and Par2/ mice.
Because of the morphological location of Kupffer cells
within the liver, the mechanical procedure used to homog-
enize the liver for fractionation of CD8þ and CD11bþ cell
populations appears to predominantly isolate the recruited
BM-derived immune cells. FACS analysis indicated that the
majority (approximately 90%) of all liver MNCs isolated
from GFPþ BM transplanted donors are GFPþ (data not
shown). Thus, this procedure does not appear to result in a
signiﬁcant isolation of resident Kupffer cells, which are long
lived and radiation resistant. These results suggest a model
in which TF tail signaling contributes to hepatic macro-
phage recruitment and TFePAR2 signaling regulates
macrophage IL-10 expression. By contrast, TFePAR2
signaling contributes to hepatic CD8þ T cell accumulation,
as well as TNF-aemediated and IFN-gemediated inﬂam-
matory pathways, in this cell population.533
Wang et alOur present ﬁndings suggest that hematopoietic AMPK
may link TFePAR2 signaling to hepatic inﬂammation and
downstream pathways of gluconeogenesis and lipogenesis. In
addition to its role in regulation of gluconeogenesis and lip-
ogenesis,31e36,42e44 AMPK has potent anti-inﬂammatory
effects.45 It suppresses NF-kB signaling,46 and hematopoi-
etic AMPK regulates obesity-induced inﬂammation and
whole-body glucose homeostasis.47 AMPK is the major
target for the widely prescribed antidiabetic drug metformin,
which inhibits hepatic gluconeogenesis, reduces blood
glucose, and improves lipid and whole-body metabolism.48,49
Despite such metabolically favorable actions of AMPK, its
regulatory mechanisms are not fully understood. In addition
to signaling through G proteins, PAR2 also signals in a G
proteineindependent manner through cytosolic recruitment
of b-arrestin, which suppresses AMPK activation.37 Inhibi-
tion of TFePAR2 complex in hematopoietic cells signiﬁ-
cantly increased AMPK activity, suggesting that
hematopoietic TFePAR2 signaling is a potential pathway
that blunts hepatic AMPK in obesity. Inﬂammatory pathways
in addition can suppress AMPK phosphorylation and activ-
ity,50 suggesting an alternative mechanism in which
hematopoietic TFePAR2emediated inﬂammation could
indirectly blunt AMPK. These direct and indirect mecha-
nisms of TFePAR2emediated inhibition of AMPK activa-
tion in the obese liver require further investigation.
In summary, here we have provided the ﬁrst in vivo
evidence that hematopoietic TFePAR2 signaling negatively
regulates the activation of hepatic AMPK and is associated
with increased inﬂammatory responses and with pathways
of steatosis and hepatic insulin resistance. Given that AMPK
plays an important role in the regulation of energy meta-
bolism and inﬂammation, novel strategies targeting AMPK
signaling via inhibition of PAR2 may provide promising
therapies to reverse chronic inﬂammation, glucose and lipid
abnormalities associated with obesity, and type 2 diabetes.
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